Nexilico, a pioneer in precision microbiome engineering, and Siolta Therapeutics, a leader in the development of live biotherapeutic products (LBPs), have entered into a collaboration agreement to address necrotizing enterocolitis (NEC) using innovative microbial therapeutics. This partnership combines Nexilico's modality-agnostic AI-driven discovery platform with Siolta’s expertise in developing targeted biotherapeutics, setting the stage for innovative treatment approaches in infant health.
UCSF congratulates both Professor Susan Lynch, the principal investigator who developed Siolta's core technology, and Nikole Kimes, her grad student who launched Siolta as a successful business with that technology. Both co-founders deserve the rewards for their good work.